SecBot SecBot
DEFA14A ·Filed Apr 24, 2026

SANA

Sana Biotechnology, Inc.
NEUTRAL
Impact 4/10
Horizonimmediate Processed6mo ago SEC0001193125-26-174886
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for any unexpected opposition or shareholder activism at the meeting, though the board's endorsement and recent reclassification suggest a routine vote. The auditor ratification is standard practice.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.29
T+0 close · Apr 24, 2026 · via day close
Latest settled
−3.95%
T+60 · $3.16
Vs SPY
−9.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 24 $3.29entry
  2. T+1 · 7mo ago −0.91%α −1.08% · $3.26
  3. T+5 · 7mo ago 0.00%α −0.91% · $3.29
  4. T+20 · 6mo ago −4.26%α −8.28% · $3.15
  5. T+60 · 4mo ago −3.95%α −9.03% · $3.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sana Biotechnology's board is seeking shareholder approval to elect three Class II directors and ratify the appointment of Ernst & Young as auditors. This follows a recent board reclassification to balance director classes, indicating ongoing governance adjustments.

Key Financial Metrics

Vote
director election
Meeting
2026-06-04
Seats Contested
3

Key Facts

  • Proxy statement seeks approval for three Class II director nominees: Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D.
  • Proposal to ratify Ernst & Young as independent auditors for 2026.
  • Follows a recent board reclassification of Steven D. Harr from Class I to Class III to balance board classes.
  • No other business is expected at the annual meeting.

Financial Impact

No direct financial impact disclosed; governance matters.

director_electionauditor_appointment

Risk Factors

  • Potential for shareholder dissent not disclosed in the filing.
  • Ernst & Young's auditor independence could be questioned if significant non-audit fees are present.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-174886
Document: 0001193125-26-174886-index-headers.html0001193125-26-174886
Document: 0001193125-26-174886-index.html0001193125-26-174886
Document: 0001193125-26-174886.txt0001193125-26-174886

Track record

12 reports on SANA

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +13.50% at T+20 after the May 11, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.37 Now $1.88 −20.68% settles Dec 7
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
  3. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  4. Aug 10, 202614w ago Press Release Neutral 4/10 Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
  5. May 11, 202627w ago 8-K Neutral 4/10 No price data
  6. May 11, 202627w ago Press Release Bearish 6/10 Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 4/10 Viewing Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  8. Apr 24, 202629w ago 8-K Neutral 2/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  9. Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
  10. Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026